Last reviewed · How we verify
NCT06814899: FOSFOREAL LIFE
Use of Fosfomycin in the Treatment of Bacterial Infections
trial testing Fosfomycin in Analyze the Medical Records of Patients Admitted At ASST Lecco from 01/04/2020 to 31/12/2023 Treated with Fosfomycin IV in 300 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | Azienda Ospedaliera di Lecco |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 April 2020 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 January 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Fosfomycin (FOSFOMYCIN) — full drug profile →
Conditions studied
- Analyze the Medical Records of Patients Admitted At ASST Lecco from 01/04/2020 to 31/12/2023 Treated with Fosfomycin IV — all drugs for Analyze the Medical Records of Patients Admitted At ASST Lecco from 01/04/2020 to 31/12/2023 Treated with Fosfomycin IV →
Sponsor
Azienda Ospedaliera di Lecco — full company profile →
Who can join
18 and older, any sex, with Analyze the Medical Records of Patients Admitted At ASST Lecco from 01/04/2020 to 31/12/2023 Treated with Fosfomycin IV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Fosfomycin is an antibiotic discovered since 1969. Disodium fosfomycin, for intravenous use (C3H5Na2O4P) is a bactericidal antibiotic, available in Italy since 2019 (AIFA approval). It works by blocking the enzyme UDP-N-acetylglucosamine enolpyruvil transferase, inhibiting the synthesis of peptidoglycan. It binds poorly to plasma proteins and is distributed very well in various tissues such as: eyes, bones, skin and subcutaneous tissue, muscles, lungs, prostate, bile and inflamed meninges. It also has a strong anti-biofilm activity. Fosfomycin is active against Gram-positive bacteria (staphylococci, streptococci, enterococci, including MRSA and VRE) and Gram-negative bacteria (Enterobacterales, Haemophilus influenzae, Proteus mirabilis, Pseudomonas aeruginosa, including MDR strains) and against difficult-to-treat bacteria such as Serratia marcescens, Stenotrophomonas maltophilia, Bacteroides spp and intracellular bacteria such as Chlamydia and Mycoplasma. It has no activity against Acinetobacter spp, Peptococcus spp. and Peptostreptococcus spp, Burkholderia cepacia, and Mycobacterium tuberculosis. IV fosfomycin is approved for the treatment of osteomyelitis, complicated urinary tract infections, pneumonia including hospital-acquired and ventilator-associated pneumonia, complicated skin and soft tissue infections, bacterial meningitis, and complicated bacteremia. In this retrospective study, the investigators want to analyze the medical records of all patients admitted to the ASST of Lecco from 01/04/2020 to 31/12/2023 treated with fosfomycin IV in order to evaluate different clinical outcomes given the recent introduction at ASST Lecco
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Intravenous Fosfomycin for Gram-Negative and Gram-Positive Bacterial Infections: A Systematic Review of the Clinical Evidence.
Falagas ME, Kontogiannis DS, Romanos LT, Ragias D, et al · · 2025 · PMID 41463696 · DOI 10.3390/antibiotics14121193
Verify or expand the search:
- PubMed search for NCT06814899
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fosfomycin
Trials testing the same drug.
- NCT05260554 — Effect of Cranberry Extract on the Urinary System · completed
- NCT05254808 — EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care · Phase 3 · terminated
- NCT03950544 — The Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae · EARLY_PHASE1 · unknown
- NCT03228108 — Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy. · Phase 4 · completed
- NCT05211011 — Efficacy and Safety of Intravenous Fosfomycin in Prosthetic Joint Infection · Phase 4 · unknown
Other Azienda Ospedaliera di Lecco trials
Trials by the same sponsor.
- NCT06424925 — Use of Artificial Intelligence (AI) to Predict Clinical Outcomes in Patients Hospitalized for COVID19 Pneumonia During t · not yet recruiting
- NCT06334185 — Evaluation of Vaccination for Streptococcus Pneumoniae in Adults With an Episode of Invasive Pneumococcal Infection. · not yet recruiting
- NCT06426212 — Use of Teicoplanin on a Three-weekly Administration in the Infectious Diseases Unit · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06814899 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliera di Lecco
- Last refreshed: 7 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06814899.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing